Tharimmune (NASDAQ:THAR) Shares Up 1.6% – Here’s What Happened

Shares of Tharimmune, Inc. (NASDAQ:THAR) rose 1.6% on Wednesday . The stock traded as high as $1.91 and last traded at $1.90. Approximately 378,180 shares were traded during mid-day trading, a decline of 74% from the average daily volume of 1,476,877 shares. The stock had previously closed at $1.87.

Tharimmune Stock Up 1.6%

The stock has a 50 day moving average of $2.49 and a 200 day moving average of $3.35. The company has a market capitalization of $71.69 million, a price-to-earnings ratio of -0.48 and a beta of 1.43.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in THAR. XTX Topco Ltd bought a new stake in shares of Tharimmune in the 2nd quarter valued at $25,000. Drucker Wealth 3.0 LLC raised its stake in Tharimmune by 150.0% during the fourth quarter. Drucker Wealth 3.0 LLC now owns 25,337 shares of the company’s stock worth $77,000 after buying an additional 15,202 shares during the last quarter. Franklin Resources Inc. bought a new position in Tharimmune during the second quarter worth $88,000. State Street Corp raised its stake in Tharimmune by 109.0% during the fourth quarter. State Street Corp now owns 36,621 shares of the company’s stock worth $111,000 after buying an additional 19,100 shares during the last quarter. Finally, Aristides Capital LLC acquired a new position in Tharimmune in the fourth quarter valued at $253,000. Institutional investors own 1.16% of the company’s stock.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc for the development of proprietary targeted biologics; and Washington University in St.